ClinicalTrials.gg
CompletedNCT05162755Updated May 12, 2026

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

A Phase 1 interventional study of S095029 and S95029 and Sym021 in Solid Tumor, sponsored by Institut de Recherches Internationales Servier. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Institut de Recherches Internationales Servier · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations.

*The study sponsor has made the decision not to move forward to the expansion part of the study due to strategic considerations, unrelated to any safety issues or concerns. The study will be stopped after completion of dose escalation parts 1a and 1b of the study.

02

Conditions studied

  • Solid Tumor

Keywords

  • Adults
  • Advanced solid tumors
  • Sym21
  • Futuximab/modotuximab
  • Triplet combination
  • Anti-EGFR
  • Anti-HER2
03

In context

Lead sponsor

Institut de Recherches Internationales Servier is the lead sponsor of 68 studies on the registry; 5 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 9 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Dose escalation part:

Inclusion criteria

Inclusion Criteria:

  • or cytologically confirmed unresectable, locally advanced or solid tumor
  • Patients with a malignancy not amenable to surgical intervention
  • Patients with and progression radiologically assessed
  • Patients with disease progression after treatment with available standard of care therapies that are known to confer clinical benefit or who are intolerant to treatment.
  • Patients with available archived tumor specimens or agree to mandatory biopsy
  • Estimated ≥ 12 weeks
  • Adequate haematological function
  • Adequate renal function
  • Adequate hepatic function

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating women
  • Major surgery within 4 weeks prior to the first IMP administration or not recovered from the surgery
  • Patients with serious/active/uncontrolled infection or infection requiring parenteral antibiotics, within 2 weeks prior to first IMP administration
  • Active Virus infection
  • Carriers of antibodies
  • Patients with active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration
  • History of organ transplantation
  • History of gastrointestinal perforation, or intra-abdominal abscess within 28 days of inclusion
  • History of cirrhosis
  • History of pulmonary fibrosis or relevant uncontrolled chronic pulmonary condition
  • Treatment with systemic therapy
  • Active disease
  • Administration of a within 28 days prior to inclusion
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Dose escalation 1a: S95029

    Drug: S095029

  • Experimental
    Dose escalation 1b: S95029 and Sym021

    Drug: S95029 and Sym021

Interventions

  • DrugAnti-NKG2A Monoclonal Antibody Sym025Studies of Anti-NKG2A Monoclonal Antibody Sym025Anti-NKG2A Monoclonal Antibody Sym025 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    S095029 will be administered via IV infusion every 2 weeks. Once the DLT evaluations period at the second dose level is completed and it is deemed as safe, the dose escalation part 1b will be initiated.

  • DrugS95029 and Sym021

    Sym021 will be administered at a fixed dose of 200mg. S095029 will be administered via IV infusion every 2 weeks. Once the RP2D dose of S95029 in combination with Sym21 is defined, dose expansion will begin.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs) (Dose escalation part)

    Incidence, severity, and relationship of AEs

    Time frame: Through study completion, up to 2 years

  2. Incidence of dose limiting toxicities (DLTs) (Dose escalation part)

    DLTs observed during a 28-day period

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

Secondary outcomes

  1. Objective Response Rate

    Time frame: Through study completion, up to 2 years

  2. Clinical Benefit Rate (CBR)

    Assessment based on complete response, partial response and stable disease ≥ 6 months

    Time frame: Through study completion, up to 2 years

  3. Duration of response (DOR)

    Time frame: Through study completion, up to 2 years

  4. Progression Free Survival (PFS)

    Time frame: Through study completion, up to 2 years

  5. Overall Survival (OS)

    Time frame: Through study completion, up to 2 years

07

Study locations

5 sites
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • The START Center for Cancer Care
    San Antonio, Texas 78229, United States
  • Princess Margaret Cancer Centre
    Toronto, Canada
08

References and documents

Publications

  • Naing A, Spreafico A, Barve M, Patnaik A, Ianopoulos X, Drean P, Skartved NJ, Hemon A, Kantari-Mimoun C, He P, Askoxylakis V, Lakhani N. Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. J Immunother Cancer. 2026 May 8;14(5):e014325. doi: 10.1136/jitc-2025-014325. PubMed 42103356 ↗

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorisation in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Feb 2024, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Dec 17, 2021
StartActual
Oct 15, 2021
Primary completionActual
Feb 1, 2024
CompletionActual
May 5, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05162755
Lead sponsor
Institut de Recherches Internationales Servier
Collaborators
ADIR, a Servier Group company
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Oct 15, 2021
Primary completion
Feb 1, 2024
Completion
May 5, 2026
Last update
May 12, 2026

Study contacts

Nehal Lakhani MD, MD, PhD
principal investigator · Director of Clinical Research START Midwest

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-NKG2A Monoclonal Antibody Sym025

Start the discussion